An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Sara Fisher Ellison & Catherine Wolfram, 2001. "Pharmaceutical Prices and Political Activity," NBER Working Papers 8482, National Bureau of Economic Research, Inc.
- Ellison, Sara Fisher & Mullin, Wallace P, 2001. "Gradual Incorporation of Information: Pharmaceutical Stocks and the Evolution of President Clinton's Health Care Reform," Journal of Law and Economics, University of Chicago Press, vol. 44(1), pages 89-129, April.
- Tomas J. Philipson & Ernst R. Berndt & Adrian H. B. Gottschalk & Matthew W. Strobeck, 2005.
"Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts,"
NBER Working Papers
11724, National Bureau of Economic Research, Inc.
- Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Strobeck, Matthew W., 2005. "Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts," Working Papers 199, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Henry G. Grabowski, 1968. "The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum Industries," Journal of Political Economy, University of Chicago Press, vol. 76(2), pages 292-292.
- Bronwyn H. Hall, 1992.
"Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?,"
NBER Working Papers
4096, National Bureau of Economic Research, Inc.
- Bronwyn H. Hall., 1992. "Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?," Economics Working Papers 92-194, University of California at Berkeley.
- Hall, Bronwyn H., 1992. "Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?," Department of Economics, Working Paper Series qt5j59j6x3, Department of Economics, Institute for Business and Economic Research, UC Berkeley.
- R. Glenn Hubbard, 1998.
"Capital-Market Imperfections and Investment,"
Journal of Economic Literature, American Economic Association, vol. 36(1), pages 193-225, March.
- R. Glenn Hubbard, 1997. "Capital-Market Imperfections and Investment," NBER Working Papers 5996, National Bureau of Economic Research, Inc.
- Steven M. Fazzari & R. Glenn Hubbard & Bruce C. Petersen, 1988.
"Financing Constraints and Corporate Investment,"
Brookings Papers on Economic Activity, Economic Studies Program, The Brookings Institution, vol. 19(1), pages 141-206.
- Steven Fazzari & R. Glenn Hubbard & Bruce C. Petersen, 1987. "Financing Constraints and Corporate Investment," NBER Working Papers 2387, National Bureau of Economic Research, Inc.
- Joseph H. Golec & John A. Vernon, 2006. "European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending," NBER Working Papers 12676, National Bureau of Economic Research, Inc.
- John A. Vernon, 2005. "Examining the link between price regulation and pharmaceutical R&D investment," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 1-16, January.
- Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck, 2005.
"Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process,"
NBER Chapters, in: Frontiers in Health Policy Research, Volume 8,
National Bureau of Economic Research, Inc.
- Berndt Ernst R. & Gottschalk Adrian H. B. & Philipson Tomas & Strobeck Matthew W., 2005. "Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process," Forum for Health Economics & Policy, De Gruyter, vol. 8(1), pages 1-25, January.
- Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck, 2004. "Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process," NBER Working Papers 10822, National Bureau of Economic Research, Inc.
- Henry Grabowski & John Vernon, 1990. "A New Look at the Returns and Risks to Pharmaceutical R&D," Management Science, INFORMS, vol. 36(7), pages 804-821, July.
- Eduardo S. Schwartz, 2003. "Patents and R&D as Real Options," NBER Working Papers 10114, National Bureau of Economic Research, Inc.
- Branch, Ben, 1974. "Research and Development Activity and Profitability: A Distributed Lag Analysis," Journal of Political Economy, University of Chicago Press, vol. 82(5), pages 999-1011, Sept./Oct.
- Joseph Golec & Shantaram Hegde & John A. Vernon, 2005. "Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending," NBER Working Papers 11229, National Bureau of Economic Research, Inc.
- Henry Grabowski & John Vernon, 2000. "The determinants of pharmaceutical research and development expenditures," Journal of Evolutionary Economics, Springer, vol. 10(1), pages 201-215.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Chorniy, Anna & Bailey, James & Maloney, Michael & Civan, Abdulkadir, 2019. "Regulatory Review Time and Pharmaceutical R&D," Working Papers 06923, George Mason University, Mercatus Center.
- Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
- Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
- Casey B. Mulligan, 2021. "Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation," NBER Working Papers 29574, National Bureau of Economic Research, Inc.
- Vincenzo Atella & Joanna Kopinska, 2018. "New Technologies and Costs," CEIS Research Paper 442, Tor Vergata University, CEIS, revised 09 Aug 2018.
- John Vernon & Joseph Golec & J. Stevens, 2010. "Comparative Effectiveness Regulations and Pharmaceutical Innovation," PharmacoEconomics, Springer, vol. 28(10), pages 877-887, October.
- Tomas J. Philipson & George Zanjani, 2013. "Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension," NBER Working Papers 19005, National Bureau of Economic Research, Inc.
- Joseph P. Cook & Graeme Hunter & John A. Vernon, 2010. "Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures," NBER Working Papers 15723, National Bureau of Economic Research, Inc.
- Boakye, Derrick & Sarpong, David & Mordi, Chima, 2022. "Regulatory review of new product innovation: Conceptual clarity and future research directions," Technological Forecasting and Social Change, Elsevier, vol. 175(C).
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- John A. Vernon, 2005. "Examining the link between price regulation and pharmaceutical R&D investment," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 1-16, January.
- Bryan P. Schmutz & Rexford E. Santerre, 2013. "Examining The Link Between Cash Flow, Market Value, And Research And Development Investment Spending In The Medical Device Industry," Health Economics, John Wiley & Sons, Ltd., vol. 22(2), pages 157-167, February.
- Giaccotto, Carmelo & Santerre, Rexford E & Vernon, John A, 2005. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry," Journal of Law and Economics, University of Chicago Press, vol. 48(1), pages 195-214, April.
- Joseph P. Cook & Graeme Hunter & John A. Vernon, 2010. "Generic Utilization Rates, Real Pharmaceutical Prices, and Research and Development Expenditures," NBER Working Papers 15723, National Bureau of Economic Research, Inc.
- Alfredo Bobillo & Juan Rodriguez Sanz & Fernando Tejerina Gaite, 2009. "Investment Decisions, Liquidity, and Institutional Activism: An International Study," Journal of Business Ethics, Springer, vol. 87(1), pages 25-40, April.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Lee, Daeyong, 2018. "Impact of the excise tax on firm R&D and performance in the medical device industry: Evidence from the Affordable Care Act," Research Policy, Elsevier, vol. 47(5), pages 854-871.
- Michele Cincera, 2003.
"Financing constraints, fixed capital and R&D investment decisions of Belgian firms,"
Chapters, in: Paul Butzen & Catherine Fuss (ed.), Firms’ Investment and Finance Decisions, chapter 6, pages 129-152,
Edward Elgar Publishing.
- Michele Cincera, 2002. "Financing constraints, fixed capital and R&D investment decisions of belgian firms," Working Paper Research 32, National Bank of Belgium.
- Michele Cincera, 2003. "Financing constraints, fixed capital and R&D investment decisions of Belgian firms," ULB Institutional Repository 2013/883, ULB -- Universite Libre de Bruxelles.
- Joseph H. Golec & John A. Vernon, 2006. "European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending," NBER Working Papers 12676, National Bureau of Economic Research, Inc.
- Stephan Eger & Jörg Mahlich, 2014. "Pharmaceutical regulation in Europe and its impact on corporate R&D," Health Economics Review, Springer, vol. 4(1), pages 1-9, December.
- Guariglia, Alessandra & Liu, Pei, 2014. "To what extent do financing constraints affect Chinese firms' innovation activities?," International Review of Financial Analysis, Elsevier, vol. 36(C), pages 223-240.
- Dirk Czarnitzki & Hanna Hottenrott & Susanne Thorwarth, 2011.
"Industrial research versus development investment: the implications of financial constraints,"
Cambridge Journal of Economics, Cambridge Political Economy Society, vol. 35(3), pages 527-544.
- Czarnitzki, Dirk & Hottenrott, Hanna & Thorwarth, Susanne, 2009. "Industrial research versus development investment: the implications of financial constraints," ZEW Discussion Papers 09-049, ZEW - Leibniz Centre for European Economic Research.
- Grabowski, Henry & Vernon, John & DiMasi, Joseph, 2002.
"Returns on R&D for 1990s New Drug Introductions,"
Working Papers
02-21, Duke University, Department of Economics.
- Henry Grabowski & John Vernon & Joseph DiMasi, 2003. "Returns on R&D for 1990s New Drug Introductions," Levine's Working Paper Archive 618897000000000666, David K. Levine.
- Hanna Hottenrott & Bronwyn H. Hall & Dirk Czarnitzki, 2016.
"Patents as quality signals? The implications for financing constraints on R&D,"
Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 25(3), pages 197-217, April.
- Czarnitzki, Dirk & Hall, Bronwyn H. & Hottenrott, Hanna, 2014. "Patents as quality signals? The implications for financing constraints on R&D," DICE Discussion Papers 133, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
- Hottenrott, Hanna & Hall, Bronwyn H & Czarnitzki, Dirk, 2016. "Patents as quality signals? The implications for financing constraints on R&D," Department of Economics, Working Paper Series qt4cr497qv, Department of Economics, Institute for Business and Economic Research, UC Berkeley.
- Hottenrott H. & Czarnitzki D. & Hall, B.H., 2014. "Patents as quality signals? The implications for financing constraints on R&D," MERIT Working Papers 2014-013, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
- Bronwyn Hall, 2014. "Patents as Quality Signals? The Implications for Financing Constraints on R&D," National Institute of Economic and Social Research (NIESR) Discussion Papers 430, National Institute of Economic and Social Research.
- Dirk Czarnitzki & Bronwyn H. Hall & Hanna Hottenrott, 2014. "Patents as Quality Signals? The Implications for Financing Constraints on R&D," NBER Working Papers 19947, National Bureau of Economic Research, Inc.
- Czarnitzki, Dirk & Hall, Bronwyn H. & Hottenrott, Hanna, 2014. "Patents as quality signals? The implications for financing constraints on R&D," ZEW Discussion Papers 14-023, ZEW - Leibniz Centre for European Economic Research.
- Giorgio Fagiolo & Alessandra Luzzi, 2006.
"Do liquidity constraints matter in explaining firm size and growth? Some evidence from the Italian manufacturing industry,"
Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 15(1), pages 1-39, February.
- Giorgio Fagiolo & Alessandra Luzzi, 2004. "Do Liquidity Constraints Matter in Explaining Firm Size and Growth? Some Evidence from the Italian Manufacturing Industry," LEM Papers Series 2004/08, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
- Hanna Hottenrott & Bettina Peters, 2012.
"Innovative Capability and Financing Constraints for Innovation: More Money, More Innovation?,"
The Review of Economics and Statistics, MIT Press, vol. 94(4), pages 1126-1142, November.
- Hottenrott, Hanna & Peters, Bettina, 2009. "Innovative capability and financing constraints for innovation: More money, more innovation?," ZEW Discussion Papers 09-081, ZEW - Leibniz Centre for European Economic Research.
- Hottenrott, Hanna & Peters, Bettina, 2012. "Innovative capability and financing constraints for innovation: More money, more innovation?," ZEW Discussion Papers 09-081 [rev.2], ZEW - Leibniz Centre for European Economic Research.
- Hottenrott, Hanna & Peters, Bettina, 2011. "Innovative capability and financing constraints for innovation: More money, more innovation?," ZEW Discussion Papers 09-081 [rev.], ZEW - Leibniz Centre for European Economic Research.
- MORIKAWA Masayuki, 2012. "Financial Constraints in Intangible Investments: Evidence from Japanese firms," Discussion papers 12045, Research Institute of Economy, Trade and Industry (RIETI).
- Joseph Golec & Shantaram Hegde & John A. Vernon, 2005. "Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending," NBER Working Papers 11229, National Bureau of Economic Research, Inc.
- Jian Xu & Jae-Woo Sim, 2018. "Characteristics of Corporate R&D Investment in Emerging Markets: Evidence from Manufacturing Industry in China and South Korea," Sustainability, MDPI, vol. 10(9), pages 1-18, August.
- Jason G. Cummins & Kevin A. Hassett & Stephen D. Oliner, 2006.
"Investment Behavior, Observable Expectations, and Internal Funds,"
American Economic Review, American Economic Association, vol. 96(3), pages 796-810, June.
- Cummins, Jason & Hassett, Kevin & Oliner, Stephen, 1997. "Investment Behavior, Observable Expectations and Internal Funds," Working Papers 97-30, C.V. Starr Center for Applied Economics, New York University.
- Jason G. Cummins & Kevin A. Hassett & Stephen D. Oliner, 1999. "Investment behavior, observable expectations, and internal funds," Finance and Economics Discussion Series 1999-27, Board of Governors of the Federal Reserve System (U.S.).
More about this item
Keywords
FDA Prescription drug user fee act R&D spending;Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:quaeco:v:49:y:2009:i:4:p:1260-1274. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/inca/620167 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.